INTRODUCTION: Irreversible electroporation (IRE) is a novel technology used in the minimally invasive treatment of small solid organ tumours. Currently, there is a paucity of literature studying treatment of small renal masses (SRMs) with IRE. Our pilot study is the first case series in Canada to use IRE in the treatment of SRMs. METHODS: This retrospective cohort pilot study includes five patients (three females and two males) who presented with a SRM that was deemed not amendable to any other treatment than a radical nephrectomy or IRE. The IRE procedures were carried out by an interventional radiologist in conjunction with a urologist using the Angiodynamics NanoKnife IRE device. RESULTS: Mean tumour size was 28 mm (range 18-39), with a mean R.E.N.A.L. nephrometry score of 8.4±0.55. Over a mean followup of 22.8 months (range 14-31), four out of the five patients did not have a radiological recurrence. No adverse events were reported after the five IRE procedures. Renal function was stable post-IRE, with no to negligible decreases in estimated glomerular filtration rate detected (range +2 to -13 mL/min/1.73 m2). CONCLUSIONS: Our pilot study demonstrates that renal percutaneous IRE is safe to use in the context of challenging-to-treat SRMs. Early radiological and renal function outcomes are encouraging, but further study is required to assess oncological success. The small sample size, retrospective nature of the study, relatively short followup, and the lack of routine renal biopsy to confirm malignancy are the major limitations noted.
INTRODUCTION: Irreversible electroporation (IRE) is a novel technology used in the minimally invasive treatment of small solid organ tumours. Currently, there is a paucity of literature studying treatment of small renal masses (SRMs) with IRE. Our pilot study is the first case series in Canada to use IRE in the treatment of SRMs. METHODS: This retrospective cohort pilot study includes five patients (three females and two males) who presented with a SRM that was deemed not amendable to any other treatment than a radical nephrectomy or IRE. The IRE procedures were carried out by an interventional radiologist in conjunction with a urologist using the Angiodynamics NanoKnife IRE device. RESULTS: Mean tumour size was 28 mm (range 18-39), with a mean R.E.N.A.L. nephrometry score of 8.4±0.55. Over a mean followup of 22.8 months (range 14-31), four out of the five patients did not have a radiological recurrence. No adverse events were reported after the five IRE procedures. Renal function was stable post-IRE, with no to negligible decreases in estimated glomerular filtration rate detected (range +2 to -13 mL/min/1.73 m2). CONCLUSIONS: Our pilot study demonstrates that renal percutaneous IRE is safe to use in the context of challenging-to-treat SRMs. Early radiological and renal function outcomes are encouraging, but further study is required to assess oncological success. The small sample size, retrospective nature of the study, relatively short followup, and the lack of routine renal biopsy to confirm malignancy are the major limitations noted.
Authors: Johann J Wendler; Maciej Pech; Frank Fischbach; Julian Jürgens; Björn Friebe; Daniel Baumunk; Markus Porsch; Simon Blaschke; Daniel Schindele; Sandra Siedentopf; Jens Ricke; Martin Schostak; Jens Köllermann; Uwe B Liehr Journal: Urology Date: 2018-01-02 Impact factor: 2.649
Authors: L G P H Vroomen; E N Petre; F H Cornelis; S B Solomon; G Srimathveeravalli Journal: Diagn Interv Imaging Date: 2017-08-30 Impact factor: 4.026
Authors: Noah E Canvasser; Igor Sorokin; Aaron H Lay; Monica S C Morgan; Asim Ozayar; Clayton Trimmer; Jeffrey A Cadeddu Journal: World J Urol Date: 2017-03-02 Impact factor: 4.226
Authors: Kenneth R Thomson; Wa Cheung; Samantha J Ellis; Dean Federman; Helen Kavnoudias; Deirdre Loader-Oliver; Stuart Roberts; Peter Evans; Christine Ball; Andrew Haydon Journal: J Vasc Interv Radiol Date: 2011-03-25 Impact factor: 3.464
Authors: Maciej Pech; Andreas Janitzky; Johann Jacob Wendler; Christof Strang; Simon Blaschke; Oliver Dudeck; Jens Ricke; Uwe-Bernd Liehr Journal: Cardiovasc Intervent Radiol Date: 2010-08-15 Impact factor: 2.740
Authors: Hester J Scheffer; Karin Nielsen; Marcus C de Jong; Aukje A J M van Tilborg; Jenny M Vieveen; Arthur R A Bouwman; Sybren Meijer; Cornelis van Kuijk; Petrousjka M P van den Tol; Martijn R Meijerink Journal: J Vasc Interv Radiol Date: 2014-03-18 Impact factor: 3.464
Authors: Mikhail Silk; David Tahour; Govindarajan Srimathveeravalli; Stephen B Solomon; Raymond H Thornton Journal: Semin Intervent Radiol Date: 2014-06 Impact factor: 1.513
Authors: Tze Min Wah; James Lenton; Jonathan Smith; Paul Bassett; Satinder Jagdev; Christy Ralph; Naveen Vasudev; Selina Bhattarai; Michael Kimuli; Jon Cartledge Journal: Eur Radiol Date: 2021-03-30 Impact factor: 5.315